Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C61319
http://purl.obolibrary.org/obo/NCIT_C61319
|
|---|---|
| Preferred Name | Tozasertib Lactate |
| Definitions |
The lactate salt of tozasertib, a synthetic, small-molecule Aurora kinase inhibitor with potential antitumor activity. Tozasertib binds to and inhibits Aurora kinases (AKs), thereby inducing apoptosis in tumor cells in which AKs are overexpressed. AKs, a family of serine-threonine kinases, are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation, and cytokinesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The lactate salt of tozasertib, a synthetic, small-molecule Aurora kinase inhibitor with potential antitumor activity. Tozasertib binds to and inhibits Aurora kinases (AKs), thereby inducing apoptosis in tumor cells in which AKs are overexpressed. AKs, a family of serine-threonine kinases, are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation, and cytokinesis. |
|---|---|
| prefLabel | Tozasertib Lactate
|
| label | Tozasertib Lactate
|
| PDQ_Closed_Trial_Search_ID | 485305
|
| code | C61319
|
| Has_Target | |
| prefixIRI | NCIT:C61319
|
| in_subset |
See more
See less
|
| Display_Name | Tozasertib Lactate
|
| Preferred_Name | Tozasertib Lactate
|
| FDA_UNII_Code | CN8EF9N084
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C23H28N8OS.C3H6O3
|
| Maps_To | Tozasertib Lactate
|
| CAS_Registry | 899827-04-4
|
| NCI_Drug_Dictionary_ID | 485305
|
| Legacy Concept Name | MK-0457
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 485305
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1451033
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |